Rafael pharmaceuticals crosses enrollment of 150 patients in pivotal phase 3 trial (armada 2000) of cpi-613® (devimistat) for relapsed or refractory acute myeloid leukemia (aml)

Company meets enrollment milestones to support research and development of a new and novel treatment for hard-to-treat cancer company meets enrollment milestones to support research and development of a new and novel treatment for hard-to-treat cancer
RFL Ratings Summary
RFL Quant Ranking